Enviar artigo por via de e-mail Specific Activity of Recombinant Modified Human Glucagon-Like Peptide 1
- Autores: Sannikova E.P.1, Bobkova N.V.2, Tatarnikova O.G.2, Yarotskii S.V.1, Askerova E.V.1, Rykalina N.V.1, Yurin V.L.1, Gracheva T.S.1, Klebanov F.A.1, Zalunin I.A.1, Cheperegin S.E.1, Bulushova N.V.1, Kozlov D.G.1
-
Afiliações:
- State Research Institute for Genetics and Selection of Industrial Microorganisms of the National Research Center, Kurchatov Institute (GOSNIIGENETIKA, NRC, Kurchatov Institute)
- Institute of Cell Biophysics, Russian Academy of Sciences
- Edição: Volume 55, Nº 7 (2019)
- Páginas: 722-732
- Seção: Producers, Biology, Selection, and Gene Engineering
- URL: https://journals.rcsi.science/0003-6838/article/view/153089
- DOI: https://doi.org/10.1134/S0003683819070068
- ID: 153089
Citar
Acesso aberto
Acesso está concedido
Somente assinantes
Resumo
An1 original drug, Glypin, has been developed for the treatment of type-II human diabetes mellitus. Its active pharmaceutical substance is a completely biosynthetic, recombinant, modified, human glucagon-like peptide (rmGlp-1) obtained via culturing of E. coli cells. In addition to the GLP-1 portion, which contains the well-known Ala8Gly substitution, the rmGLP-1 protein has an additional amino acid sequence at the C-terminus that includes the heparin-binding peptide of human HB-EGF. Preclinical testing of Glypin specific activity (with Lixumia as a reference drug) was performed. A commercial preparation of Lixumia served as the main reference drug for comparison with the specific activity of Glypin. During preclinical studies of both medicines, it was shown that Glypin and Lixumia have similar mechanisms, power, and time of action upon subcutaneous and intramuscular introductions, as well as comparable therapeutic effects under long-term use. Based on these data, the subcutaneous injection was selected as the main therapeutic method of Glypin administration; the minimal effective dose for Glypin preclinical study was established as 100 μg/kg body mass, and a single dose for human treatment was defined as 0.75 and 1.5 mg. The intranasal introduction of Glypin was observed to have a statistically reliable positive effect on the cognitive capacities of a mouse with Alzheimer’s disease model. The similarity of the characteristics of Glypin and Lixumia shown in our study make it possible to expect that they will have equal therapeutic efficacy with daily use of a single dose.
Sobre autores
E. Sannikova
State Research Institute for Genetics and Selection of Industrial Microorganisms of the National Research Center,Kurchatov Institute (GOSNIIGENETIKA, NRC, Kurchatov Institute)
Email: dg_kozlov@genetika.ru
Rússia, Moscow, 117545
N. Bobkova
Institute of Cell Biophysics, Russian Academy of Sciences
Email: dg_kozlov@genetika.ru
Rússia, Pushchino, Moscow oblast, 142290
O. Tatarnikova
Institute of Cell Biophysics, Russian Academy of Sciences
Email: dg_kozlov@genetika.ru
Rússia, Pushchino, Moscow oblast, 142290
S. Yarotskii
State Research Institute for Genetics and Selection of Industrial Microorganisms of the National Research Center,Kurchatov Institute (GOSNIIGENETIKA, NRC, Kurchatov Institute)
Email: dg_kozlov@genetika.ru
Rússia, Moscow, 117545
E. Askerova
State Research Institute for Genetics and Selection of Industrial Microorganisms of the National Research Center,Kurchatov Institute (GOSNIIGENETIKA, NRC, Kurchatov Institute)
Email: dg_kozlov@genetika.ru
Rússia, Moscow, 117545
N. Rykalina
State Research Institute for Genetics and Selection of Industrial Microorganisms of the National Research Center,Kurchatov Institute (GOSNIIGENETIKA, NRC, Kurchatov Institute)
Email: dg_kozlov@genetika.ru
Rússia, Moscow, 117545
V. Yurin
State Research Institute for Genetics and Selection of Industrial Microorganisms of the National Research Center,Kurchatov Institute (GOSNIIGENETIKA, NRC, Kurchatov Institute)
Email: dg_kozlov@genetika.ru
Rússia, Moscow, 117545
T. Gracheva
State Research Institute for Genetics and Selection of Industrial Microorganisms of the National Research Center,Kurchatov Institute (GOSNIIGENETIKA, NRC, Kurchatov Institute)
Email: dg_kozlov@genetika.ru
Rússia, Moscow, 117545
F. Klebanov
State Research Institute for Genetics and Selection of Industrial Microorganisms of the National Research Center,Kurchatov Institute (GOSNIIGENETIKA, NRC, Kurchatov Institute)
Email: dg_kozlov@genetika.ru
Rússia, Moscow, 117545
I. Zalunin
State Research Institute for Genetics and Selection of Industrial Microorganisms of the National Research Center,Kurchatov Institute (GOSNIIGENETIKA, NRC, Kurchatov Institute)
Email: dg_kozlov@genetika.ru
Rússia, Moscow, 117545
S. Cheperegin
State Research Institute for Genetics and Selection of Industrial Microorganisms of the National Research Center,Kurchatov Institute (GOSNIIGENETIKA, NRC, Kurchatov Institute)
Email: dg_kozlov@genetika.ru
Rússia, Moscow, 117545
N. Bulushova
State Research Institute for Genetics and Selection of Industrial Microorganisms of the National Research Center,Kurchatov Institute (GOSNIIGENETIKA, NRC, Kurchatov Institute)
Email: dg_kozlov@genetika.ru
Rússia, Moscow, 117545
D. Kozlov
State Research Institute for Genetics and Selection of Industrial Microorganisms of the National Research Center,Kurchatov Institute (GOSNIIGENETIKA, NRC, Kurchatov Institute)
Autor responsável pela correspondência
Email: dg_kozlov@genetika.ru
Rússia, Moscow, 117545
Arquivos suplementares
